Global Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Clinical Trials Market Report, H2 2021 Review – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

The report provides an overview of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency).

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Key Topics Covered:

• Report Guidance
• Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Countries Contributing to Clinical Trials in Middle East and Africa
• Top Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) to Immunology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Clinical Trials
• Prominent Drugs
• Clinical Trial Profile Snapshots
• Appendix

Companies Mentioned

• Takeda Pharmaceutical Co Ltd
• BioCryst Pharmaceuticals Inc
• Pharming Group NV
• CSL Ltd
• Kalvista Pharmaceuticals Inc
• Pharvaris BV
• Watch Bidco Ltd
• Ionis Pharmaceuticals Inc
• Advanced Medical Services GmbH
• AMS Advanced Medical Services GmbH

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/dnttgp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900